FDA Classifies Philips Lumify Ultrasound Recall as Class I After Eight Injuries and Four Deaths
The U.S. Food and Drug Administration classified a safety action by Philips Ultrasound regarding its Lumify diagnostic ultrasound system as a Class I recall, the most severe category. The recall requires updated instructions rather than removing devices from service. A software flaw in the Lumify application can cause the app to fail to recognize a registered transducer, unexpectedly blocking scanning until the user completes re-registration. Re-registration requires an active Wi-Fi or cellular signal, which creates risks in pre-hospital environments like ambulances or field settings. Additionally, physical USB cable connections between transducers and mobile devices can loosen or disconnect. These technical problems can delay diagnosis and care during urgent point-of-care medical procedures. As of September 29, 2026, Philips reported eight serious injuries and four deaths connected to the issue. The FDA advises healthcare providers to use the devices only where cellular or Wi-Fi coverage is available, or where a backup scanner is ready.
What was announced
On October 19, 2026, the US Food and Drug Administration classified a correction of Philips Lumify diagnostic ultrasound systems as a Class I recall. This classification is the FDA's most serious recall level, reserved for situations where device use can cause severe injury or death.
The issue involves both Android and iOS software versions of the Philips Lumify system, which links an ultrasound transducer cable to a phone or tablet. Philips sent a notice to customers on September 24, 2026, warning that a software fault can prompt the system to demand transducer re-registration without prior warning. Users cannot scan until re-registration is finished, which requires Wi-Fi or cellular service. Additionally, the physical USB connection between the transducer cable and mobile device can disconnect or become unstable. As of September 29, 2026, Philips reported eight serious injuries and four deaths associated with these device failures.
What it means
Medical staff use portable ultrasound devices for fast decision-making, fluid analysis, and patient triage. These tools often operate in mobile or remote settings like ambulances and aircraft where internet access is unavailable or unreliable.
When software unexpectedly locks scanning functionality outside of internet coverage, clinicians cannot perform needed diagnostic scans. Unstable USB connections create further disruptions during continuous imaging. In emergency settings, these unexpected delays in diagnosis or care can cause severe patient harm.
Philips is not removing the Lumify hardware from service. Instead, the company directs operators to use the devices only in areas with accessible cellular or Wi-Fi signals unless an immediate backup scanner is present. Healthcare facilities must also share the warning notice with staff and post it near affected units.
What the announcement does not tell us
The FDA announcement leaves several operational details unanswered:
- The update schedule for the software patch is not specified.
- No timeline or fix is provided for the unstable physical USB cable connections.
- Specific clinical details about the reported injuries and deaths are omitted.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA MedWatch Safety Alerts’s own. Always check the original before acting on anything here.
A software app or transducer connection problem with the Philips Lumify diagnostic ultrasound system can result in loss of or delays in scanning functionality.
Opens www.fda.gov
More from FDA MedWatch Safety Alerts
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.